Several vitamin D analogues like 1α,25(OH)2D3 (i.e., calcitriol) and 25(OH)2D3 (i.e., cholecalciferol) were used for the treatment of secondary hyperparathyroidism (sHPT) among CKD patients but their efficacy is often limited since it triggers hypercalcemia [3] and also the efficacy of these drugs is largely determined by efficient binding with VDR. Here, VDR is linked to chronic kidney disease.